Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Oric Pharmaceuticals, Inc. (ORIC : NSDQ)

• Company Description    ORIC Pharmaceuticals Inc. is a clinical stage oncology company. It is focused on developing treatments which address mechanisms of therapeutic resistance. The company's product candidate consists of ORIC-101 and ORIC-533 which are in clinical stage. ORIC Pharmaceuticals Inc. is based in San Francisco, United States. Number of Employees: 115

• Price / Volume Information    Yesterday's Closing Price: $11.14 Daily Weekly Monthly 20 Day Moving Average: 854,744 shares Shares Outstanding: 85.22 (millions) Market Capitalization: $949.40 (millions) Beta: 1.54 52 Week High: $14.67 52 Week Low: $3.90 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 20.82% 14.75% 12 Week 114.64% 86.95% Year To Date 38.04% 28.93%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 240 E. GRAND AVE. 2ND FLOOR - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-388-5600 fax: - investors@oricpharma.com http://www.oricpharma.com

• General Corporate Information    Officers Jacob M. Chacko - Chief Executive Officer and President Richard Heyman - Chairman Dominic Piscitelli - Chief Financial Officer Mardi Dier - Director Steven Hoerter - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 68622P109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 85.22 Most Recent Split Date: (:1) Beta: 1.54 Market Capitalization: $949.40 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.44 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.74 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.60 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -13.51% vs. Previous Quarter: 17.65% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -51.14 12/31/24 - -44.54 ROA 06/30/25 - - 03/31/25 - -46.29 12/31/24 - -40.72 Current Ratio 06/30/25 - - 03/31/25 - 12.00 12/31/24 - 10.56 Quick Ratio 06/30/25 - - 03/31/25 - 12.00 12/31/24 - 10.56 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 3.09 12/31/24 - 3.45 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©